eligibility_summary
Eligible must: follow reproductive criteria, have completed a qualifying Parent Study, have been on elranatamab at its end, and be deriving benefit per investigator. Exclude: medical/psychiatric conditions (including recent—past year—or active suicidal ideation) or lab abnormalities increasing risk, and those not enrolled in the Parent Study or who discontinued its treatment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Elranatamab (Elrexfio), a humanized, full-length bispecific IgG2 kappa antibody given as monotherapy in an open-label, single-arm post-trial access Phase 4 study. Mechanism of action: T-cell–redirecting bispecific that binds BCMA (B-cell maturation antigen) on multiple myeloma (malignant plasma) cells and CD3 on T cells, forming an immune synapse, activating TCR/CD3 signaling, and inducing T cell–mediated cytotoxicity and cytokine release to kill BCMA-positive cells. Targets/pathways: BCMA (TNFRSF17) on myeloma cells, CD3/TCR complex on T lymphocytes.